Scientific and Technical Program

Development and implementation of innovative pressurized intraperitoneal aerosol chemotherapy (PIPAC) in the comprehensive treatment of patients with locally advanced gastric cancer.

• Develop personalized indications for pressurized intraperitoneal aerosol chemotherapy in patients with locally advanced gastric cancer.
• Develop a nozzle for an effective intraperitoneal aerosol chemotherapy regimen and compare the incidence of postoperative complications.
• Assess overall and recurrence-free survival in patients receiving neoadjuvant chemotherapy and radical surgery with the developed PIPAC method, compared with patients treated without PIPAC.

Development and implementation of innovative intrapleural hyperthermic chemotherapy (HITHOC) in the comprehensive treatment of patients with primary and metastatic pleural involvement.

• Develop personalized indications for intrapleural hyperthermic chemotherapy following cytoreductive surgery.
• Develop a method of intrapleural hyperthermic chemotherapy and assess postoperative complications.
• Assess overall and recurrence-free survival following cytoreductive surgery using the developed method.

Development and implementation of an innovative breast reconstruction technology using a domestically produced acellular xenogeneic matrix.

• Develop a technique for immediate breast reconstruction after mastectomy with implant fixation using an acellular xenogeneic matrix.
• Evaluate the clinical effectiveness of an acellular xenogeneic matrix in primary breast reconstruction.
• Conduct a comparative assessment of reconstructive outcomes using an acellular xenogeneic matrix versus polypropylene mesh in terms of aesthetic results and postoperative complications.
• Conduct a comparative analysis of patients’ quality of life.

Develop a method for breast reconstruction after radical surgery using a decellularized xenomatrix in combination with lymphovenular anastomoses in patients with breast cancer.

• Conduct a comparative analysis of the clinical effectiveness of the developed reconstruction method.
• Conduct a comparative analysis of patients’ quality of life when lymphovenular anastomoses are used in the postoperative period.

Establish production of a new-generation immunomodulatory product based on pharmacopeial monosaccharides in combination with sodium citrate and introduce it into medical practice.

• Establish the scientific and technological foundations for production and develop technological regulations.
• Produce pilot batches and develop regulatory and methodological documents for quality control.
• Conduct a comprehensive set of preclinical and biomedical studies to assess safety and immunomodulatory activity.
• Investigate the mechanism of immunomodulatory action.
• Study the product as a dietary supplement for the treatment, prevention, and palliative therapy of oncological diseases.
• Launch small-scale production and register the developed product.

In 2025, recruitment to the control group was completed, and clinical validation of PIPAC as part of neoadjuvant treatment for locally advanced gastric cancer continued.

Interim analysis showed no serious adverse events among patients who received PIPAC, supporting an acceptable safety profile of the method in the preoperative setting.

In 2026, recruitment to the main study group and publication of study results continued.

An article was published in Frontiers in Oncology: “Incidence of peritoneal carcinomatosis after perioperative FLOT chemotherapy in gastric cancer: single-center analysis in Kazakhstan.”

The article “Anesthetic Management During PIPAC: Clinical and Practical Aspects” was published in the Journal of Clinical Medicine of Kazakhstan, 2026, 23(2):39–44, DOI: 10.23950/jcmk/18357.

A standardized HITHOC protocol was developed and implemented, including cytoreductive surgery, hyperthermic chemoperfusion, and postoperative management.

Recruitment of patients with pleural malignancies and evaluation of short- and long-term treatment outcomes are ongoing.

The article “First report of pleural mesothelioma treated with cytoreductive surgery and hyperthermic intrathoracic chemotherapy in Kazakhstan: a case report” was published in the Journal of Medical Case Reports, 2026. DOI: 10.1186/s13256-026-06112-w.

The article “Оценка эффективности и безопасности гипертермической интраторакальной химиотерапии (HITHOC) при злокачественных плевральных заболеваниях” was published in the Eurasian Journal of Oncology and Radiology, No. 2, 2026. DOI: 10.52532/3135-3940-2026-2-698.

The patent “Method for reducing systemic toxicity during hyperthermic intrathoracic chemotherapy (HITHOC) using an adsorbent” was approved.

A clinical study was conducted to comparatively assess breast reconstruction using an acellular xenogeneic matrix and polypropylene mesh, as well as prophylactic lymphovenular anastomosis.

In 2026, the planned recruitment to the main and control groups presented in the current program report was completed.

The patent “Method for microsurgical formation of a lymphovenous anastomosis (LVA) with enhanced connection stability in oncologic reconstructive surgery” was approved.

The monograph “Breast Cancer” (Zh.K. Burkitbayev, B.B. Anapiya, A.V. Ogizbayeva) was prepared; the current report states that it is ready for approval.

The article “Evaluation of a national breast cancer screening program in a middle-income country: the case of Kazakhstan” was published in the International Journal of Environmental Research and Public Health.

In 2025, pilot batches of the KFM immunomodulatory product were produced, and regulatory and methodological documents for quality control of intermediate and final products were developed.

In 2026, in vivo biomedical studies of the immunomodulatory and antitumor activity of KFM were conducted using a colorectal cancer model.

The current report notes that the combination of KFM with 5-fluorouracil demonstrated pronounced suppression of tumor growth and increased survival in experimental animals.

Product State Registration Certificate No. KZ.16.01.98.003.R.000450.07.26 dated 30 July 2026 was obtained.

The dietary supplement “KFM — Monosaccharide Complex” was registered. Manufacturer: SAGA PHARM LLP under a special order from Al-Farabi Kazakh National University.

1. Yuliya Semenova, Altay Kerimkulov, Talgat Uskenbayev, Dinara Zharlyganova, Oxana Shatkovskaya, Tomiris Sarina, Almira Manatova, Gulfairus Yessenbayeva, Tasbolat Adylkhanov. Chemotherapy Options for Locally Advanced Gastric Cancer: A Review // Cancers. 2025. 17:809. DOI: 10.3390/cancers17050809.

   Open publication

2. Yuliya Semenova, Zhandos Burkitbayev, Nurtas Kalibekov, Alexandr Digay, Bakhyt Zhaxybayev, Oxana Shatkovskaya, Saule Khamzina, Dinara Zharlyganova, Zhuldyz Kuanysh, Almira Manatova. The Evolving Role of Chemotherapy in the Management of Pleural Malignancies: Current Evidence and Future Directions // Cancers. 2025. 17:2143. DOI: 10.3390/cancers17132143.

   Open publication

3. Zarina A. Kenessova, Grigoriy A. Mun, Perizat I. Urkimbayeva, Assel K. Toktabayeva, Raikhan K. Rakhmetullayeva, Bayana B. Yermukhambetova, Zhazira Kenzhebai, Zhuldyzay T. Kurmanova, Mubarak Yermaganbetov, Adilet Zh. Alikulov. Development and Characterization of Polymer Blends Based on Polyvinyl Alcohol for Application as Pharmaceutical Dosage Form // Polymers. 2025. 17:2203. DOI: 10.3390/polym17162203.

   Open publication

4. Sergey A. Dergunov, Grigoriy A. Mun, Bayana B. Yermukhambetova, Adilet Zh. Alikulov. Molecular and structural insights into the thermoresponsive behavior of pyrrolidone-based LCST polymers in aqueous solution // European Polymer Journal. 2025. 240:114343. DOI: 10.1016/j.eurpolymj.2025.114343.

   Open publication

5. Жумабаев М.Б., Батырбекова Н.А., Әнапия Б.Б., Умбетжанов Е.У., Садвакасова А.К., Буркитбаев Ж.К., Манатова А.М., Куаныш Ж.М., Жумабаев Р.Б., Иримбетов С.Б. Comparative analysis of the effectiveness of traditional postoperative analgesia and ESP block in radical bilateral mastectomy // Наука и Здравоохранение. 2025. 27(4):36–43. DOI: 10.34689/SH.2025.27.4.005.

   Open publication

6. Болсынбекова С.О., Тулеубаева А.А., Ганиева Е.Д., Урезкова М.М., Гоголев А.Б., Пак Л.А. Patterns of development of pathomorphological tumor regress after neoadjuvant chemotherapy for gastric cancer: experience of the National Research Oncology Center // Наука и Здравоохранение. 2025. 27(4):21–28. DOI: 10.34689/SH.2025.27.4.003.

   Open publication

7. Tomiris Sarina, Temirlan Kainazarov, Dina Kovalchuk, Zhandos Burkitbayev, Almira Manatova, Zhuldyz Kuanysh, Sanzhar Shalekenov. Real-World Experience of Perioperative Chemotherapy for Gastric Cancer in Kazakhstan: Clinical Outcomes and Economic Considerations // Astana Medical Journal. 2025. 125(4). DOI: 10.54500/2790-1203-2025-4-125-amj002.

   Open publication

8. А.Л. Беркембаева, Ж.К. Буркитбаев, Д.А. Зайнулина, Ж.М. Куаныш, А.К. Керимкулов, З.Д. Душимова. Профессиональная и экологическая безопасность при лечении перитонеальных метастазов методом внутрибрюшинной аэрозольной химиотерапии под давлением: предварительный обзор // Журнал Казахстанско-Российского медицинского университета. 2025. №3. DOI: 10.64854/2790-1289-2025-49-3-10.

   Open publication

9. Сапаев М.Н., Байнаева Б.С., Джакипова М.А., Кожахметов А.М., Мамлин М.А., Керимкулов А.К., Усипбеков Б.Н., Болсынбекова С.О., Манатова А.М., Буркитбаев Ж.К. Comparative analysis of computer tomographic staging and postoperative pathomorphological staging in stomach cancer // Наука и Здравоохранение. 2025. 27(5).

1. Incidence of peritoneal carcinomatosis after perioperative FLOT chemotherapy in gastric cancer: single-center analysis in Kazakhstan // Frontiers in Oncology, 2026.

2. Anesthetic Management During PIPAC: Clinical and Practical Aspects // Journal of Clinical Medicine of Kazakhstan. 2026. 23(2):39–44. DOI: 10.23950/jcmk/18357.

   Open publication

3. First report of pleural mesothelioma treated with cytoreductive surgery and hyperthermic intrathoracic chemotherapy in Kazakhstan: a case report // Journal of Medical Case Reports. 2026. DOI: 10.1186/s13256-026-06112-w.

   Open publication

4. Оценка эффективности и безопасности гипертермической интраторакальной химиотерапии (HITHOC) при злокачественных плевральных заболеваниях // Eurasian Journal of Oncology and Radiology. 2026. №2. DOI: 10.52532/3135-3940-2026-2-698.

   Open publication

5. Evaluation of a national breast cancer screening program in a middle-income country: the case of Kazakhstan // International Journal of Environmental Research and Public Health, 2026.

1. Micro-irrigator for intracavitary spraying of a chemotherapeutic agent // Utility Model Patent No. 10568. Kazakhstan, 2025.

2. Use of an acellular xenogeneic matrix for breast reconstruction in oncology // Utility Model Patent No. 11199. Kazakhstan, 2025.

3. Method for prevention of peritoneal carcinomatosis in locally advanced gastric cancer // invention patent application No. 2025/0440.1 dated 04 March 2025; under examination according to the 2026 report.

4. Method for reducing systemic toxicity during hyperthermic intrathoracic chemotherapy (HITHOC) using an adsorbent // approved in 2026.

5. Method for microsurgical formation of a lymphovenous anastomosis (LVA) with enhanced connection stability in oncologic reconstructive surgery // approved in 2026.

6. Method for producing a water-soluble thermoresponsive copolymer with emulsifying properties // Eurasian patent; under examination according to the 2026 report.

1. Burkitbayev Zh.K., Pak L.A. “Сүт безі қатерлі ісігі: теориялық негіздері мен тәжірибелік шешімдері” — textbook; Certificate of Scientific and Medical Review No. 11-2-1/3862 dated 22 October 2025.

2. Textbook on cytoreductive surgery with intrapleural hyperthermic chemoperfusion in patients with primary and metastatic pleural involvement — listed as in progress in the current 2026 report.

3. Monograph “Breast Cancer” — Zh.K. Burkitbayev, B.B. Anapiya, A.V. Ogizbayeva; listed in the current 2026 report as prepared for approval.